Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Could more protein keep dialysis patients healthier?

NCT ID NCT07237997

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at whether eating more protein can help people on dialysis avoid hospital stays. Dialysis removes nutrients like protein from the blood, and current guidelines are based on old research. The study will give some participants a high-protein diet or supplements and track their hospital visits and overall health.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
High protein diet and modular protein supplements
What this could lead to
If it works, this could lead to better dietary guidelines for dialysis patients, potentially reducing hospital admissions and improving overall health.
What could go wrong
This is an early-stage study with no phase, and previous research is weak and outdated. The results may not show a clear benefit, and individual responses to protein intake can vary.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 114 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jan 2026

An estimate. Start dates often move.

Expected to finish

Oct 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≥ 18 years (no upper age limit) * Patients receiving maintenance dialysis for ≥ three months * Ability to provide informed consent Exclusion Criteria: * Anticipated live donor kidney transplant and/or kidney recovery within the period of sample collection. * Anticipated change of dialysis modality within the period of sample collection * Severe malnutrition based on either: * Renal 7-point Subjective Global Assessment (SGA) scores of 1-2 * Global Leadership Initiative Malnutrition (GLIM) Stage 2 * Protein-losing enteropathy. * Persistent nephrotic syndrome with \>3g/day urinary protein loss. * Active wounds or burns contributing to protein losses as judged by the investigator. * Current active acute inflammatory illness (likely to have catabolic effect in the opinion of the investigator). * Current malignancy based on recent (\<12 months) diagnosis and/or active treatment for malignancy and/or planned treatment for malignancy, excluding non-melanoma skin cancers. * Pregnancy (current or planned within duration of study) or breast feeding. * People with swallowing difficulties precluding safe ingestion (International Dysphagia Diet Standardization Initiative (IDDSI) level 0 thin fluid). * People receiving intradialytic parenteral nutrition or intra-peritoneal amino acids, or any other forms of artificial feeding * People prescribed levodopa * People who are receiving chronic glucocorticoid therapy (\>10mg day prednisolone or equivalent for \>7 days within preceding 90 days). * People who are consuming a protein dietary intake above 1.5g protein/kg/body weight. * People who, in the opinion of the investigator, will be unable to comply with study protocol requirements. * People who are vegan or other religious based dietary restrictions which would prevent them taking the supplement.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Dialysis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Centre for Kidney Research and Innovation (CKRI), Academic Unit for Translational Medical Sciences School of Medicine (Royal Derby Hospital Campus)

    Nottingham, NG7 2QL, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.